Achieve Life Sciences (ACHV) Long-Term Debt Issuances (2016 - 2017)

Achieve Life Sciences (ACHV) posted Long-Term Debt Issuances of $20000.0 for Q1 2017, down 60.0% on a QoQ basis from $50000.0 in Q4 2016.

Achieve Life Sciences (ACHV) Long-Term Debt Issuances (2016 - 2017) Analysis & Trends

Achieve Life Sciences' Long-Term Debt Issuances history runs 2 years deep, the most recent figure standing at $20000.0 for Q1 2017.

Quarterly Long-Term Debt Issuances changed N/A year-over-year to $20000.0 in Q1 2017, while the trailing twelve-month figure through Dec 2024 was $70000.0 (changed N/A YoY) and the FY2024 annual result came in at $9.8 million, changed N/A from the prior year.
Long-Term Debt Issuances was $20000.0 for Q1 2017 at Achieve Life Sciences, down from $50000.0 in the prior quarter.
Across five years, Long-Term Debt Issuances topped out at $50000.0 in Q4 2016 and bottomed at $20000.0 in Q1 2017.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Debt Issuances (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	-
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	-
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Achieve Life Sciences	2.54 Mn	2.54 Mn	-	-

Download Data